Research Hotspots and Frontiers of Immunotherapy for Prostate Cancer: A Visual Analysis
10.3971/j.issn.1000-8578.2022.21.1486
- VernacularTitle:前列腺癌免疫治疗研究热点的可视化分析
- Author:
Tongtong JIN
1
;
Chuan ZHOU
;
Chao WANG
;
Zijian DA
;
Fenghai ZHOU
Author Information
1. The First School of Clinical Medicine, Lanzhou University, Lanzhou 730000, China
- Publication Type:Research Article
- Keywords:
Prostatic neoplasms;
Immunotherapy;
Immune checkpoint inhibitors;
Bibliometrics;
Visualization analysis
- From:
Cancer Research on Prevention and Treatment
2022;49(7):667-674
- CountryChina
- Language:Chinese
-
Abstract:
Objective To visualize and analyze the literature related to immunotherapy for prostate cancer published in the past 20 years through bibliometric analysis, and to explore the research progress and cutting-edge trends in this field. Methods The Web of Science core collection database was searched for literature related to immunotherapy for prostate cancer published from 2002 to 2021. CiteSpace and VOSviewer software were used to visualize and analyze the data and map the evolution of hotspots. Results There were 2 326 papers were finally included after excluding irrelevant studies. The field of immunotherapy for prostate cancer is in a rapid development stage; the United States has a great influence and China has a significant latecomer advantage; the National Cancer Institute, Memorial Sloan-Kettering Cancer Center and University of California, San Francisco are the main research institutions; American authors Gulley JL, Schlom J and Japanese author Itoh K have the highest number of publications. Currently, the main research hotspot is immune checkpoint inhibitors, and high-quality clinical trials are continuing to drive this process forward. Conclusion The exploration of novel immune pathways and the combination of different therapies will be the main trend of future research in immunotherapy for prostate cancer.
